Arbutus Biopharma Corp cotiza a 4.11 USD y tiene una capitalización bursátil de $630M. En los últimos 12 meses ha facturado $182M con un margen de flujo de caja libre del -281.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clin…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.04 | $1.19 | $-0.01 | $-0.06 |
| Estimado | $-0.03 | $-0.05 | $-0.05 | $-0.05 |
| Sorpresa | -33.3% | +2480.0% | +80.0% | -20.0% |
| Métrica | ABUS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -271.0% | -38.6% | -232.3% |
| Net Margin | -237.9% | -33.6% | -204.3% |
| FCF Margin | -281.4% | -13.9% | -267.6% |
| ROE | -43.8% | -40.4% | -3.4% |
| ROA | -35.4% | -32.0% | -3.4% |
| Current Ratio | 15.73 | 2.84 | +12.89 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |